LABELS · 1922dbd9-96de-8652-e063-6294a90a0afe

LEVOTHYROXINE SODIUM

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2024-05-23
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].

Indications and usage: exact source text

Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)] . Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Full extracted label fields

application numbers

NDA021116
ANDA209713

boxed warning exact

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including levothyroxine sodium tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6), Drug Interactions (7.7), and Overdosage (10)].

brand names

LEVOTHYROXINE SODIUM

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a5f15022-1166-09fe-e053-2a95a90aa218

generic names

LEVOTHYROXINE SODIUM

1922dbd9-96de-8652-e063-6294a90a0afe

indications and usage exact

Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)] . Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

indications and usage tables exact

is original packager

manufacturer names

DIRECT RX

matched search terms

cancer

package ndcs

72189-159-30
72189-159-90
72189-173-90
72189-173-30
72189-155-90
72189-155-30
72189-073-90
72189-073-30
72189-107-30
72189-107-90
72189-160-30
72189-160-90

product ndcs

72189-073
72189-159
72189-173
72189-155
72189-107
72189-160
72189-163
72189-174
72189-206
72189-250

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

892246
966220
966221
966222
966224
966225
966248
966253
966270

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

meta

disclaimer

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

last updated

2026-09-09

license

https://open.fda.gov/license/

results

limit: 100
skip: 0
total: 830

terms

https://open.fda.gov/terms/

sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

url

source url

https://api.fda.gov/drug/label.json?search=id%3A%221922dbd9-96de-8652-e063-6294a90a0afe%22

spl effective date

2024-05-23

spl effective time

20240523

spl set id

a5f15022-1166-09fe-e053-2a95a90aa218

spl version

substance names

LEVOTHYROXINE SODIUM

uniis

9J765S329G

verification flags

oncology_keyword_candidate_not_clinically_classified
spl_text_not_verified_identical_to_latest_approved_label
individual_indications_not_split_or_reconciled
not_identified_as_original_packager

Drugs@FDA application source records

application number
ANDA209713
payload
all indexed label documents
all submission records
Appl No
209713
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
32
Submission Status
AP
Submission Status Date
2024-09-24 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
209713
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
29
Submission Status
AP
Submission Status Date
2023-07-21 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
209713
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
16
Submission Status
AP
Submission Status Date
2023-07-21 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
209713
Review Priority
UNKNOWN
Submission Class Code ID
4
Submission No
3
Submission Status
AP
Submission Status Date
2019-06-03 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
209713
Review Priority
STANDARD
Submission Class Code ID
19
Submission No
1
Submission Status
AP
Submission Status Date
2019-01-18 00:00:00
Submission Type
ORIG
Submissions Public Notes
application number
ANDA209713
approval interpretation
Application linkage and approved submission are not indication-level current approval verification
current indication status
not_reconciled
drugsfda url
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209713
has approved submission record
true
latest approved submission date
2024-09-24
latest label selection rule
max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
latest posted label documents
official application record
Appl No
209713
Appl Public Notes
Appl Type
ANDA
Sponsor Name
LUPIN
openfda application present
true
products
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
001
Reference Drug
0
Reference Standard
0
Strength
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
002
Reference Drug
0
Reference Standard
0
Strength
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
003
Reference Drug
0
Reference Standard
0
Strength
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
004
Reference Drug
0
Reference Standard
0
Strength
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
005
Reference Drug
0
Reference Standard
0
Strength
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
006
Reference Drug
0
Reference Standard
0
Strength
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
007
Reference Drug
0
Reference Standard
0
Strength
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
008
Reference Drug
0
Reference Standard
0
Strength
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
009
Reference Drug
0
Reference Standard
0
Strength
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
010
Reference Drug
0
Reference Standard
0
Strength
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
011
Reference Drug
0
Reference Standard
0
Strength
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
209713
Drug Name
LEVOTHYROXINE SODIUM
Form
TABLET;ORAL
Product No
012
Reference Drug
0
Reference Standard
0
Strength
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
application number
NDA021116
payload
all indexed label documents
Appl No
021116
Application Docs Date
2002-10-24 00:00:00
Application Docs ID
36151
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21116lbl.pdf
Submission No
1
Submission Type
ORIG
Appl No
021116
Application Docs Date
2006-03-14 00:00:00
Application Docs ID
36152
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021116s006lbl.pdf
Submission No
6
Submission Type
SUPPL
Appl No
021116
Application Docs Date
2017-09-01 00:00:00
Application Docs ID
49659
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021116s013lbl.pdf
Submission No
13
Submission Type
SUPPL
Appl No
021116
Application Docs Date
2019-04-25 00:00:00
Application Docs ID
58413
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021116s017lbl.pdf
Submission No
17
Submission Type
SUPPL
Appl No
021116
Application Docs Date
2023-11-17 00:00:00
Application Docs ID
76605
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021116s027lbl.pdf
Submission No
27
Submission Type
SUPPL
all submission records
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
27
Submission Status
AP
Submission Status Date
2023-11-16 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
23
Submission Status
AP
Submission Status Date
2022-04-14 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
21
Submission Status
AP
Submission Status Date
2021-12-13 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
17
Submission Status
AP
Submission Status Date
2019-04-23 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
16
Submission Status
AP
Submission Status Date
2016-05-19 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
14
Submission Status
AP
Submission Status Date
2015-11-09 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
13
Submission Status
AP
Submission Status Date
2017-08-31 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
12
Submission Status
AP
Submission Status Date
2015-01-13 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
6
Submission Status
AP
Submission Status Date
2006-03-10 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
4
Submission Status
AP
Submission Status Date
2004-12-07 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
15
Submission No
1
Submission Status
AP
Submission Status Date
2002-10-24 00:00:00
Submission Type
ORIG
Submissions Public Notes
application number
NDA021116
approval interpretation
Application linkage and approved submission are not indication-level current approval verification
current indication status
not_reconciled
drugsfda url
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021116
has approved submission record
true
latest approved submission date
2023-11-16
latest label selection rule
max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
latest posted label documents
Appl No
021116
Application Docs Date
2023-11-17 00:00:00
Application Docs ID
76605
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021116s027lbl.pdf
Submission No
27
Submission Type
SUPPL
official application record
Appl No
021116
Appl Public Notes
Appl Type
NDA
Sponsor Name
ALVOGEN
openfda application present
true
products
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
001
Reference Drug
1
Reference Standard
0
Strength
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
002
Reference Drug
1
Reference Standard
0
Strength
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
003
Reference Drug
1
Reference Standard
0
Strength
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
004
Reference Drug
1
Reference Standard
0
Strength
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
005
Reference Drug
1
Reference Standard
0
Strength
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
006
Reference Drug
1
Reference Standard
0
Strength
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
007
Reference Drug
1
Reference Standard
0
Strength
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
008
Reference Drug
1
Reference Standard
0
Strength
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
009
Reference Drug
1
Reference Standard
0
Strength
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
010
Reference Drug
1
Reference Standard
0
Strength
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
011
Reference Drug
1
Reference Standard
0
Strength
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
012
Reference Drug
1
Reference Standard
0
Strength
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · positive indication candidate

application numbers

NDA021116
ANDA209713

brand names

LEVOTHYROXINE SODIUM

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 396
end exclusive: true
exact text: Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-depen
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 0

current approval status

not_reconciled

duplicate text group

dup-c24d2c750044003c629e

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-7883017894fd1cc1cc9b

label id

1922dbd9-96de-8652-e063-6294a90a0afe

positive predicate support span

end: 57
end exclusive: true
exact text: are indicated
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 44

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 196
end exclusive: true
exact text: Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%221922dbd9-96de-8652-e063-6294a90a0afe%22

spl effective date

2024-05-23

spl set id

a5f15022-1166-09fe-e053-2a95a90aa218

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 2 · positive indication candidate

application numbers

NDA021116
ANDA209713

brand names

LEVOTHYROXINE SODIUM

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 636
end exclusive: true
exact text: Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefit
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 0

current approval status

not_reconciled

duplicate text group

dup-dfccd01b958453ee37fb

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-213354ba46eea16a69b3

label id

1922dbd9-96de-8652-e063-6294a90a0afe

positive predicate support span

end: 308
end exclusive: true
exact text: are indicated
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 295

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 436
end exclusive: true
exact text: Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 197

source url

https://api.fda.gov/drug/label.json?search=id%3A%221922dbd9-96de-8652-e063-6294a90a0afe%22

spl effective date

2024-05-23

spl set id

a5f15022-1166-09fe-e053-2a95a90aa218

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 3 · limitation of use

application numbers

NDA021116
ANDA209713

brand names

LEVOTHYROXINE SODIUM

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 885
end exclusive: true
exact text: ng Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)] . Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 237

current approval status

not_reconciled

duplicate text group

dup-93c5bb66887e68f3b4de

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-a8084a754b30d7fc17b5

label id

1922dbd9-96de-8652-e063-6294a90a0afe

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 755
end exclusive: true
exact text: Limitations of Use: Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)] .
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 437

source url

https://api.fda.gov/drug/label.json?search=id%3A%221922dbd9-96de-8652-e063-6294a90a0afe%22

spl effective date

2024-05-23

spl set id

a5f15022-1166-09fe-e053-2a95a90aa218

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 4 · limitation of use

application numbers

NDA021116
ANDA209713

brand names

LEVOTHYROXINE SODIUM

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 885
end exclusive: true
exact text: ic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)] . Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 556

current approval status

not_reconciled

duplicate text group

dup-be0841f2e058370a8df4

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-a45ff5bfac9ad9937993

label id

1922dbd9-96de-8652-e063-6294a90a0afe

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 885
end exclusive: true
exact text: Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 1922dbd9-96de-8652-e063-6294a90a0afe
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: 3fb9f359e3d161693d678e620f664d18e8ba806e1a346a93784ba488e4189629
start: 756

source url

https://api.fda.gov/drug/label.json?search=id%3A%221922dbd9-96de-8652-e063-6294a90a0afe%22

spl effective date

2024-05-23

spl set id

a5f15022-1166-09fe-e053-2a95a90aa218

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice